EBS News 25.44 Emergent Biosolutions (EBS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Emergent Biosolutions (EBS) 25.44 $EBS

Pharma-Bio 2Q14 Update: $9 Billion in Project Starts Reflects 91% Gain in Industry Capital Investment, an Industrial Info News Alert
Marketwire - Fri Apr 18, 5:15AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- When June 2014 draws to a close, the Pharmaceutical-Biotech Industry is forecast to have launched nearly $9 billion worth of North American capital and maintenance projects during the previous three months. The stunning number reflects a 91% increase over last year's figures.

Emergent BioSolutions Gains on Trial News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:10PM CDT
Emergent BioSolutions is looking to expand BioThrax's label.

Emergent BioSolutions to Participate in May 2014 Investor Conferences
Business Wire - Thu Apr 17, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company's senior management team will participate in the following investor conferences in May 2014:

Emergent BioSolutions Successfully Completes Pivotal Clinical Study to Support Expanded Indication for BioThrax
Business Wire - Wed Apr 16, 6:21AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced successful completion of the last licensure-enabling study in its BioThrax(R) (Anthrax Vaccine Adsorbed) Post-Exposure Prophylaxis (PEP) program. This clinical study, also known as the non-interference study, was designed to evaluate the pharmacokinetic profile of the antimicrobial ciprofloxacin when administered prior to and following the administration of a three-dose series of BioThrax. It was also designed to evaluate the immune response to BioThrax when administered with or without ciprofloxacin. The primary endpoints were the ratio of the maximum concentration (Cmax) and area under the curve (AUC) for ciprofloxacin and the secondary endpoint was the ratio of the geometric mean titer of the antibody response to BioThrax two weeks following the last dose. The study met the prospectively defined success criteria for both the primary and secondary endpoints. Data from this study show no interaction between ciprofloxacin and BioThrax.

Karen Hughes Joins Omnia Biologics
PR Newswire - Tue Apr 08, 9:49AM CDT
Biologics development and manufacturing services provider Omnia Biologics, Inc. (Omnia) (Rockville, MD) today announced that Karen Hughes has joined the Omnia team as Senior Director of Quality Assurance and Quality Control.

The Global Vaccine Market Forecast is Expected to Grow at a CAGR of around 12% during 2012-2017
M2 - Fri Mar 28, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/87zbl9/global_vaccine) has announced the addition of the "Global Vaccine Market Forecast to 2017" report to their offering. Of late, the vaccines market is burgeoning with immense activities. Big pharmaceutical companies like GSK, Pfizer, Merck etc. are struggling to maintain their revenue and operating incomes amidst patent cliffs of blockbuster drugs. In such a scenario, vaccines, which have high entry barriers for generic players and the potential to generate blockbuster sales, are increasingly alluring the players. Besides, the market has also gained momentum due to the recent technological advances that now allow the manufacturing of high efficacy combination vaccines, providing protection from a plethora of diseases in one schedule. This has resulted in the introduction of several promising vaccines, actively promoted by health agencies and non-profit organizations to offer maximum immunization coverage, especially in the developing regions with high incidence rates of infectious diseases. In the report, the vaccine market has been studied on three distinct levels: Regional, Therapeutic Category, and Company. For regional analysis, key vaccine markets that together constitute around 90% of the global market, have been profiled. Further, the market has been broken down into 16 distinct therapeutic categories and their current and future outlook to 2017 has been analyzed. Through this, our analysts have conducted a thorough opportunity assessment in various therapeutic categories and regions to clearly highlight avenues which offer maximum opportunities for growth. Companies Mentioned: - AstraZeneca Plc. - Baxter International Inc. - BioCSL (CSL Biotherapies) - Crucell - Dendreon Corporation - Emergent Biosolutions - GSK - Merck - Novartis - Pfizer - Sanofi-Pasteur - Takeda Pharmaceutical Company Limited For more information visit http://www.researchandmarkets.com/research/87...al_vaccine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Earnings Release and Presentation Schedules, Nominations, and Financial Results - Analyst Notes on Five Prime Therapeutics, Acceleron, Emergent BioSolutions, CONMED, and ImmunoGen
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Five Prime Therapeutics, Inc. (NASDAQ: FPRX), Acceleron Pharma Inc. (NASDAQ: XLRN), Emergent BioSolutions Inc. (NYSE: EBS), CONMED Corporation (NASDAQ: CNMD), and ImmunoGen, Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Emergent BioSolutions Inc. - Product Pipeline Review - 2013
M2 - Tue Mar 18, 3:54AM CDT
Summary

Pernix Therapeutics Appoints John Sedor to Its Board of Directors
Business Wire - Thu Mar 13, 11:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of John Sedor as a non-executive Director and Chairman of the Compensation Committee of its Board of Directors. Mr. Sedor has more than 30 years of proven leadership in the global pharmaceutical, biopharmaceutical, consumer product and generic drug industries. John is recognized for his entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise. Prior to his current role as President and CEO at Rodes Inc., John most recently served as President, CEO and Director of Cangene Corporation, one of the world's leading biopharmaceutical companies in the development, manufacture and commercialization of therapies targeting infectious disease, hematology/oncology and transplantation. Under his guidance, Cangene was acquired by Emergent BioSolutions in February 2014. Prior to joining Cangene, he served as President, CEO and Director of CPEX Pharmaceuticals, Inc., a specialty drug delivery pharmaceutical company, and managed its spin-off from Bentley Pharmaceuticals, Inc. Prior to that, he was President of Bentley, which expanded its nanotechnology programs and added more than 20 new product approvals in the European market under his leadership. In 1996, John created Centeon LLC to develop and commercialize plasma protein biotherapeutics. Other previous roles include President of Sandoz Inc. (Novartis), and various senior positions at Verion, Rorer Pharmaceutical Co., Revlon Health Care Group and Armour Pharmaceutical Company.

Emergent Beats on Earnings & Revenues, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:10AM CDT
Emergent had a strong quarter with both revenues and earnings coming above expectations.

Emergent BioSolutions (EBS) Soars: Stock Rises 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:51AM CDT
Emergent BioSolutions, Inc. was a big mover last session, as its shares rose nearly 9% on the day.

3 Biotech Stocks Spiking on Big Volume
at The Street - Mon Mar 10, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.

Why You Need to Pay Attention to Kamada (KMDA) Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:00AM CST
Kamada has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy. A key reason for this move has been the positive trend in the earnings estimate revisions picture.

Emergent BioSolutions reports 32% rise in GAAP net income & 11% in revenues in 2013
M2 - Fri Mar 07, 4:16AM CST
US-based pharmaceutical company Emergent BioSolutions (NYSE:EBS) disclosed on Thursday a GAAP net income of USD31.1m (USD0.86 per basic share) for the full year ended 31 December 2013.

VALNEVA Announces a New Research Agreement and Transfer of an Existing Commercial Agreement to Emergent BioSolutions for the Development of Vaccines in the EB66(R) Cell Line
Thomson Reuters ONE - Fri Mar 07, 12:30AM CST
Valneva Announces a New Research Agreement and Transfer of an Existing Commercial Agreement to Emergent BioSolutions for the Development of Vaccines in the EB66(R) Cell Line

Emergent BioSolutions Reports Financial Results for 2013
Business Wire - Thu Mar 06, 3:01PM CST
--Product sales of $257.9 million, up 19%

Weakness Seen in Synta Pharmaceuticals (SNTA): Stock Tumbles 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:54AM CST
Synta Pharmaceuticals Corp. (SNTA) saw a big move last session, reversing the recent trend for SNTA as the stock is now up around 8.4% in the past one-month time frame.

Biodel enters into commercial manufacturing agreement for Glucagon Rescue Product with Emergent BioSolutions
M2 - Thu Mar 06, 5:05AM CST
Biopharmaceutical company Biodel (NasdaqCM:BIOD) revealed on Wednesday the launch of another agreement for its Glucagon Emergency Management (GEM) development and manufacturing programme with Cangene bioPharma (Emergent BioSolutions).

Biodel Announces Commercial Manufacturing Agreement With Emergent BioSolutions for Glucagon Rescue Product
GlobeNewswire - Wed Mar 05, 3:00PM CST
Biodel Inc. (Nasdaq:BIOD) today announced another development in its Glucagon Emergency Management (GEM) development program with the signing of a long-term manufacturing agreement with Cangene bioPharma Inc. doing business as Emergent BioSolutions ("Emergent" . Under the agreement, Emergent will fill and finish commercial quantities of the GEM device. Financial terms of the agreement have not been disclosed.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Minnesota Giving Record Signals a Stressed Safety Net

Updated Category News Views 63

Thirty-eight million dollars landing in one day is no small civic heartbeat. Minnesota’s Give to the Max Day brought in a record $38.4 million in 2026 for nearly 6,000 nonprofits and schools, edging past the $37.8 million raised in 2025. More than 65,000 people gave. That deserves a clear-eyed nod, not a cynical shrug. Still, the number carries two messages at once. It...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 27

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 123

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 61

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
Ampace Targets AI Data Centre UPS Safety Needs in Paris

Updated Category News Views 109

Backup power gets interesting only after the grid has disappointed everybody. At Data Centre World Paris 2026, Ampace put its attention on that ugly, split-second handoff: utility power drops, a UPS has to catch the load immediately, and nobody operating an AI data centre gets to shrug if it does not. A Narrow Job With Brutal Consequences The company showcased its PU200...

Continue Reading
ADFW 2026 Builds a Bigger Stage for Global Capital

Updated Category News Views 30

Abu Dhabi is not merely booking conference rooms this December; it is assembling a very deliberate display of financial muscle. Abu Dhabi Finance Week runs from 7 to 10 December 2026, and ADGM says its fifth edition will carry its largest-ever programme of partner-led activity. That is a promotional claim, sure, but the partner list is substantial enough that investors...

Continue Reading
BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 119

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 68

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading

Top 5 Most Recently Viewed Articles

Allstream Insiders Unveils Industry Talks for Energy Pros

Updated Category News Views 294

Allstream Insiders Launches New Industry Talks Platform HOUSTON -- Allstream Insiders has rolled out an innovative platform called Industry Talks, specifically tailored for professionals within the energy sector. This initiative is designed to offer vital insights and a venue for sharing ideas that resonate in the New Energy markets. Focus on Career Growth and Skills A...

Continue Reading
Exploring Orexo's Pharmaceutical Innovations and IP Strategies

Updated Category News Views 130

Orexo's Insights on Pharmaceutical IP Strategies Orexo, a prominent player in the pharmaceutical industry, is poised to share its extensive knowledge in protecting intellectual property (IP) during an upcoming seminar. This event, organized in collaboration with esteemed law firms Potter Clarkson LLP and Steptoe LLP, aims to equip pharmaceutical companies, biotech firms,...

Continue Reading
Lindblad Expeditions Holdings Plans Tender Offer for Notes

Updated Category News Views 156

Lindblad Expeditions Holdings Begins Tender Offer for Senior Notes Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND) has recently announced the pricing terms of its ongoing tender offer aimed at acquiring any and all of its outstanding 6.750% Senior Secured Notes due 2027. This notable initiative is executed through its wholly-owned subsidiary, Lindblad Expeditions, LLC....

Continue Reading
Key Economic Reports to Influence Markets This Thursday

Updated Category News Views 103

Key Economic Reports to Influence Markets This Thursday As traders gear up for another pivotal day in the financial markets, several key economic reports are expected to be released. These reports could significantly impact market dynamics and sway investor sentiment. This Thursday’s lineup includes essential data on the services sector, jobless claims, and factory...

Continue Reading
Investigation Launch: Zeta Global Holdings Corp Under Scrutiny

Updated Category News Views 160

Zeta Global Holdings Corp (NYSE: ZETA) is stepping into turbulent waters with an intense investigation hovering over its officers and directors regarding possible breaches of fiduciary duty. For shareholders who’ve been riding the wave since at least February 2022, this isn’t just another corporate footnote; it’s a pressing signal that deserves attention. With the...

Continue Reading